Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy
Nada Albarakati(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Claire Seedhouse(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Rachel Doherty(University of Nottingham), Arvind Arora(Himalayan Institute Hospital Trust), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Christina J. Perry(Macquarie University), Stephen Chan(Heidelberg University), Tarek M.A. Abdel-Fatah(University of Nottingham), Ian O. Ellis(University of Nottingham), Devika Agarwal(University of Oxford), Carlos Caldas(University of Cambridge), Andrew R. Green(Nottingham Biomedical Research Centre), Nouf H. Alsubhi(King Abdulaziz University), Roslin Russell(University of Cambridge), Graham Ball(Computer Algorithms for Medicine)
Cited by 80
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770